Vaccinex, Inc. (VCNX)
| Market Cap | 2.78M +40.5% |
| Revenue (ttm) | 601.00K +5.4% |
| Net Income | -18.63M |
| EPS | -8.88 |
| Shares Out | 2.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.000 |
| Previous Close | 1.040 |
| Day's Range | 1.000 - 1.000 |
| 52-Week Range | 0.310 - 1.500 |
| Beta | 0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 17, 2026 |
About Vaccinex
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer’s disease and has completed phase 2 study for the treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 ... [Read more]
Financial Performance
In 2024, Vaccinex's revenue was $601,000, an increase of 5.44% compared to the previous year's $570,000. Losses were -$18.63 million, -7.98% less than in 2023.
Financial StatementsNews
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
ROCHESTER, N.Y., July 08, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) through the inhibiti...
Vaccinex Reports 2025 Annual Financial Results
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington...
Vaccinex announces $60M revenue sharing agreement with PDV
Vaccinex (VCNX) entered into a $60M revenue sharing agreement with Pepinemab Development Venture to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinica...
Vaccinex to reports new clinical results on pepinemab at ASCO meeting
Vaccinex (VCNX) will present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved ...
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. Neoadjuvant treatment with pepinemab appears to induce abu...
Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy
Vaccinex (VCNX) will present exciting new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies, corresponding with improved survival benefit in pat...
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinema...
Vaccinex to delist common stock from Nasdaq
Vaccine announced that it has notified Nasdaq of its decision to delist the company’s shares of common stock, par value $0.0001 per share, from Nasdaq. Trading in the Common Stock…
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating ne...
Vaccinex receives delisting notification from Nasdaq
Vaccinex (VCNX) announced that on December 16, 2024, the Company received written notice from the Office of General Counsel of The Nasdaq Stock Market indicating that the Nasdaq Hearings Panel…
Vaccinex reports Q3 EPS ($2.83) vs. ($15.25) last year
Reports Q3 revenue $52,000 vs. $20,000 last year. Cash and cash equivalents and marketable securities on September 30, 2024, were $2.9 million, as compared to $1.5 million as of December…
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Actively Exploring Partnership for Alzheimer's Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage bi...
Vaccinex provides update on ActivMAb platform
Vaccinex (VCNX) announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc and Incyte, employing Vaccinex’s ActivMAb technology ...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
Vaccinex to preset new biomarker data on HNSCC
Vaccinex (VCNX) announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, HPV-ne...
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. Pepine...
Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab
Vaccinex (VCNX) provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. Vaccinex recently announced results of the phase 1b/2 stud...
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain
Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's disease Company descri...
Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study
Vaccinex (VCNX) announced that it will present promising new efficacy and safety data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer’s disease at the...
Vaccinex files to sell 1.6M shares of common stock for holders
The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale of shares of common stock by the selling…
Vaccinex announces exercise of warrants for $6.2M in gross proceeds
Vaccinex announced the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock at the reduced exercise price of...
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
Vaccinex provide update on findings for SIGNAL-AD Phase 1b/2 trial of pepinemab
Vaccinex provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. The Company recently announced positive results of the phase 1b/2...
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership
ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's di...
Vaccinex stock tanks 40% despite positive Alzheimer's study update
Vaccinex Inc (NASDAQ: VCNX) tanked an alarming 40% on Wednesday despite it reporting positive early-stage results for its Alzheimer's treatment. The biotechnology company said its SIGNAL-AD trial est...